Company News Single-use News
ALLpaQed and Ready to Go: Single-Use Event
On 12th September 2023, ALLpaQ will head to Leiden, Netherlands to attend the prestigious Single-Use Event at CORPUS Congress Centre. […]
Sep 01st, 2023
Baxter set to acquire gene therapy company
Baxter International has agreed to acquire Chatham Therapeutics LLC, a private biotechnology company which specialises in gene therapy programmes for haemophilia.
The deal, which is valued at around $70 million initially, could see future payments made to Chatham based on development, regulatory and commercial milestones.
Ludwig Hantson, president of Baxter’s BioScience unit, said the acquisition would help further the development of treatments for the blood-clotting disorder haemophilia.
“Chatham’s gene therapy platform technology offers the potential to redefine treatment of both haemophilia A and B,” he explained in a statement.
“This technology will be highly complementary to our expanding pipeline of bleeding disorder treatments as we continue our pursuit of a bleed-free world.”
Baxter and Chatham first partnered back in May 2012 to develop potential treatments for haemophilia B.
Jade Samulski, co-founder of Chatham, added: “Given Baxter’s long-standing commitment to innovative product development in haemophilia, we are confident that this transaction provides the best opportunity for the advancement of our BNPTM gene therapy platform technology for the benefit of haemophilia patients worldwide.”
The news comes shortly after Baxter announced plans to split itself into two separate healthcare companies with one focusing on biopharmaceuticals and the other on medical products.
Related reading:
